Jazz Pharmaceuticals plc (J7Z) — Cash Flow-to-Debt Ratio
Jazz Pharmaceuticals plc (J7Z) has a Cash Flow-to-Debt Ratio of 0.06x as of March 2026, meaning its operating cash flow of €408.20 Million could theoretically repay 0% of its total liabilities (€7.33 Billion) in one year. See free cash flow generation of Jazz Pharmaceuticals plc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jazz Pharmaceuticals plc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Jazz Pharmaceuticals plc across 13 annual periods. Also explore net asset growth rate of Jazz Pharmaceuticals plc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jazz Pharmaceuticals plc (2013–2025)
Year-by-year debt coverage analysis for Jazz Pharmaceuticals plc. For market capitalisation and broader financial context, see Jazz Pharmaceuticals plc (J7Z) total market value.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.18x | €1.36 Billion | €7.34 Billion | ▲ +4.8% |
| 2024 | 0.18x | €1.40 Billion | €7.92 Billion | ▲ +23.6% |
| 2023 | 0.14x | €1.09 Billion | €7.66 Billion | ▼ -13.1% |
| 2022 | 0.16x | €1.27 Billion | €7.75 Billion | ▲ +75.7% |
| 2021 | 0.09x | €778.51 Million | €8.33 Billion | ▼ -70.1% |
| 2020 | 0.31x | €899.65 Million | €2.88 Billion | ▼ -2.2% |
| 2019 | 0.32x | €776.40 Million | €2.43 Billion | ▼ -2.1% |
| 2018 | 0.33x | €798.90 Million | €2.45 Billion | ▲ +13.6% |
| 2017 | 0.29x | €693.09 Million | €2.41 Billion | ▲ +41.9% |
| 2016 | 0.20x | €592.39 Million | €2.92 Billion | ▼ -33.9% |
| 2015 | 0.31x | €531.94 Million | €1.73 Billion | ▲ +48.1% |
| 2014 | 0.21x | €407.61 Million | €1.97 Billion | ▼ -32.3% |
| 2013 | 0.31x | €288.43 Million | €942.69 Million | — |